Mirum Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
MIRM$94.42+1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net loss | $(790,155) | $(14,677) |
| Reconciliation of net loss to net cash used in operating activities: | ||
| Stock-based compensation | 36,202 | 15,803 |
| Depreciation and amortization | 6,874 | 6,052 |
| Inventory reserves and firm commitment losses | — | 2,349 |
| Amortization of debt discount and offering costs | 454 | 433 |
| Unrealized foreign exchange loss (gain) | 1,098 | (658) |
| Non-cash lease expense | 550 | 390 |
| Fair value of common stock issued in connection with asset acquisition | 415,271 | — |
| Change in fair value of holdback liabilities | (998) | — |
| Other | (278) | (356) |
| Change in operating assets and liabilities: | ||
| Accounts receivable | (12,886) | (16,833) |
| Prepaid and other current assets | (6,630) | (3,029) |
| Inventory | (1,920) | (2,672) |
| Other assets | (4,796) | (92) |
| Accounts payable, accrued expenses and other liabilities | 57,244 | 11,737 |
| Holdback liabilities | 71,790 | — |
| Operating lease liabilities | (583) | (408) |
| Net cash used in operating activities | (228,763) | (1,961) |
| Investing activities | ||
| Purchase of investments | (34,797) | (33,526) |
| Proceeds from maturities of investments | 33,892 | 17,433 |
| Purchase of property and equipment | (664) | (41) |
| Payments made for additions to intangible assets | (10,000) | — |
| Net cash used in investing activities | (11,569) | (16,134) |
| Financing activities | ||
| Proceeds from issuance of common stock and pre-funded warrants in private placement, net of issuance costs of $8,600 | 259,948 | — |
| Proceeds from issuance of common stock pursuant to equity plans | 10,131 | 6,359 |
| Net cash provided by financing activities | 270,079 | 6,359 |
| Effect of exchange rate on cash, cash equivalents and restricted cash | (1,272) | 1,055 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 28,475 | (10,681) |
| Cash, cash equivalents and restricted cash at beginning of period | 298,165 | 222,928 |
| Cash, cash equivalents and restricted cash at end of period | $326,640 | $212,247 |
| Supplemental disclosure of cash flow information: | ||
| Operating cash flows paid for operating lease | $810 | $583 |
| Cash paid for income taxes | $220 | $162 |
| Net operating liabilities, excluding cash acquired, assumed in connection with asset acquisition | $9,561 | $— |
| Non-cash operating, investing and financing activities: | ||
| Right-of-use assets obtained in exchange for lease liabilities | $4,472 | $— |
| Decrease in ROU assets and lease liabilities due to lease modification | $— | $649 |
| Stock-based compensation capitalized to inventory | $173 | $212 |
| Conversion of convertible notes, net into shares of common stock | $— | $6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.